Europe Contraceptives Market - Segmented by Contraceptive Methods, Mode of Delivery, Type of devices, by Gender and by Geography - Growth, Trends and Forecasts (2017 - 2022)

The European market for contraceptives is estimated to be worth USD 1.29 billion in the year 2014. This market is expected to reach USD 1.87 billion by the end of 2019. During this period, the market is projected to grow at a CAGR of 7.76%.

Europe Contraceptives Market-Market Dynamics

The report details several factors driving and restraining the market. Some of these are discussed below.


Contributing to the growth of the contraceptives market globally is the necessity to avoid unwanted pregnancies and their complications. A high percentage of women who are sexually active do not want to become pregnant. The contraceptive prevalence in Europe is estimated to be 71.8%, indicating a good use of contraceptives among the population in Europe. The need to avoid unwanted pregnancies, especially in the teenage women, is one of the major drivers for this market.

It is also observed that more than half of the women identify non-contraceptive health benefits, such as treatment for excessive menstrual bleeding, menstrual pain, and acne, as reasons for use. These are some of the factors contributing to the growth of the market. The other factors helping the growth of the contraceptives market are the increasing incidence of STDs and the rapid increase in population. Government initiatives promoting the use of contraceptives to avoid unnecessary births and the health benefits from using the contraceptives have also been important players in the growth of the market.


Factors such as religious and cultural opposition in certain emerging nations have been restraining the growth of this market. Along with this, the fear of certain side effects and issues such as infertility resulting from the use of contraceptives have been major setbacks from the market point of view. Issues such as limited access to contraceptives in the developing and economically backward nations have been another setback in this market. It is estimated that among the European women, meeting the needs of family planning is estimated to be as high as 10.1%.

The European market for contraceptive drugs and devices can be segmented on the basis of the contraceptive method used, mode of delivery, type of device, gender and geography. On the basis of the contraceptive method used, the market is segmented into pills, implants, sterilization, IUDs, injectable, male condoms, vaginal barrier methods, etc. Based on the mode of delivery, the market is segmented into oral, topical and contraceptive injectable. On the basis of the device, the market is segmented into condoms, diaphragms, cervical caps, sponges and vaginal rings.

Geographically, the European market holds the second largest market share in the world. Over 80% of the female population in Europe uses the modern contraceptives techniques. The market share is estimated to be 23%.

Some of the key players in the market are:

Bayer Healthcare

Merck & Co.

Mylan Laboratories


The Female Health Company

What the Report Offers

Market definition for the European contraceptive drugs & devices market along with identification of key drivers and restraints for the market.

Market analysis for the European contraceptive drugs & devices market, with region-specific assessments and competition analysis on a global and regional scale.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their market share.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

An exhaustive understanding of the European market for contraceptives.

A comprehensive analysis of the major trends, innovations and associated prospects for market growth over the coming half a decade.

An ideal opportunity for industry consultants and other interested and allied parties to gain a critical insight into the factors driving and restraining the market, in addition to opportunities offered.

Wide-ranging information provided about the leading market players and the major strategies adopted by them.

1. Introduction

1.1 Report Description

1.2 Research Methodology

1.3 Major Stakeholders

2. Executive Summary

2.1 Key Findings

2.2 Market Overview

3. Market Overview

3.1 Market Definition

3.1.1 Introduction

3.2 Market Drivers

3.2.1 Product Innovation

3.2.2 Increasing incidence of STD's

3.2.3 Pregnancy prevention

3.2.4 Immediate Health benefits other than birth control

3.2.5 Rise in Government initiatives to prevent unwanted abortions and pregnancies

3.2.6 Rapid increase in global population

3.3 Market Restraints

3.3.1 Fear or experience of side effects

3.3.2 Cultural or Religious opposition

3.3.3 Limited access to contraception

3.3.4 Infertility issues

3.3.5 Economic constraints

3.4 Market opportunities

3.4.1 New product pipelines

3.4.2 Male Contraceptive Drugs

3.5 Porter's Five Force Analysis

3.5.1 Threat of a new entrant

3.5.2 Internal Rivalry

3.5.3 Buyer Bargaining Power

3.5.4 Supplier Bargaining Power

3.5.5 Threat of substitutes

4. Market Segmentation- Europe Market for Contraceptive Drugs and Devices

4.1 Segmentation by Contraceptive Method

4.1.1 Sterilization

4.1.2 Pills

4.1.3 Implants

4.1.4 Injectables

4.1.5 Intrauterine Device (IUD)

4.1.6 Male Condoms

4.1.7 Vaginal barrier methods

4.1.8 Others

4.2 Segmentation by Mode of Delivery

4.2.1 Oral Contraceptives

4.2.2 Topical Contraceptives

4.2.3 Contraceptive Injectables

4.3 Segmentation by type of device

4.3.1 Condoms

4.3.2 Diaphragms

4.3.3 Cervical Caps

4.3.4 Sponges

4.3.5 Vaginal Rings

4.3.6 IUD

4.3.7 Implants

4.4 Segmentation by Gender

4.4.1 Male

4.4.2 Female

4.5 Segmentation by Geography

4.5.1 Europe UK Germany France Spain Italy Others

5. Competitive Landscape

5.1 Mergers & Acquisitions

5.2 New Product Launches

5.3 Agreements, Collaborations & Partnerships

5.4 Market Chain Analysis

5.5 Price Share Analysis

5.6 Recommendations for New market players

5.7 Recommendations for Existing market players

6. Company Profiles

6.1 Bayer Healthcare

6.1.1 Overview

6.1.2 Major Products and Services

6.1.3 Financials

6.1.4 Recent Developments

6.2 Pfizer

6.2.1 Overview

6.2.2 Major Products and Services

6.2.3 Financials

6.2.4 Recent Developments

6.3 Merck & Co

6.3.1 Overview

6.3.2 Major Products and Services

6.3.3 Financials

6.3.4 Recent Developments

6.4 Teva Pharmaceuticals, Ltd.

6.4.1 Overview

6.4.2 Major Products and Services

6.4.3 Financials

6.4.4 Recent Developments

6.5 Agile Therapeutics

6.5.1 Overview

6.5.2 Major Products and Services

6.5.3 Financials

6.5.4 Recent Developments

6.6 Actavis PLC

6.6.1 Overview

6.6.2 Major Products and Services

6.6.3 Financials

6.6.4 Recent Developments

6.7 ANI Pharmaceuticals, Inc.

6.7.1 Overview

6.7.2 Major Products and Services

6.7.3 Financials

6.7.4 Recent Developments

6.8 Church & Dwight, Co. Inc.

6.8.1 Overview

6.8.2 Major Products and Services

6.8.3 Financials

6.8.4 Recent Developments

6.9 Fuji Latex Co., Ltd.

6.9.1 Overview

6.9.2 Major Products and Services

6.9.3 Financials

6.9.4 Recent Developments

6.10 Johnson & Johnson, Ltd.

6.10.1 Overview

6.10.2 Major Products and Services

6.10.3 Financials

6.10.4 Recent Developments

6.11 Lupin Pharmaceuticals, Ltd

6.11.1 Overview

6.11.2 Major Products and Services

6.11.3 Financials

6.11.4 Recent Developments

6.12 Okamato Industries, Inc.

6.12.1 Overview

6.12.2 Major Products and Services

6.12.3 Financials

6.12.4 Recent Developments

6.13 Reckitt Benckiser Group, PLC

6.13.1 Overview

6.13.2 Major Products and Services

6.13.3 Financials

6.13.4 Recent Developments

6.14 The Female Health Company

6.14.1 Overview

6.14.2 Major Products and Services

6.14.3 Financials

6.14.4 Recent Developments

6.15 Mylan Laboratories

6.15.1 Overview

6.15.2 Major Products and Services

6.15.3 Financials

6.15.4 Recent Developments

7. Appendix

7.1 Abbreviations

7.2 Sources

7.3 Bibliography

7.4 Disclaimer

Content are not available

Choose License Type